Article PDF
Avoid common mistakes on your manuscript.
References
Wang JB, Wang ZX, Jing J, Zhao P, Dong JH, Zhou YF, et al. Exploring an integrative therapy for treating COVID-19: a randomized controlled trial. Chin J Integr Med 2020;26:648–655.
Li RF, Hou YL, Huang JC, Pan WQ, Ma QH, Shi YX, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020;156:104761.
Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, et al. Efficacy and safety of Lianhuaqingwen Capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine 2020;153242. [Epub ahead of print]
Yang XB, Yuan Y, Xu JQ, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020:8:475–481.
Bauer TT, Ewig S, Rodloff AC, Müller EE. Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data. Clin Infect Dis 2006;43:748–756.
Poon PMK, Wong CK, Fung KP, Fong CYS, Wong ELY, Lau JTF, et al. Immunomodulatory effects of a traditional Chinese medicine with potential antiviral activity: a self-control study. Am J Chin Med 2006;34:13–21.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhong, Ns., Yang, Zf., Jiang, M. et al. A Potential Chinese Medicine Granule Suppressing ARDS of COVID-19: Keguan-1. Chin. J. Integr. Med. 26, 803–804 (2020). https://doi.org/10.1007/s11655-020-3437-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-020-3437-4